OraSure Technologies, Inc. Share Price
NASDAQ: OSUR | Micro CapOraSure Technologies, Inc. Stock Performance
Open $4.03 | Prev. Close $3.99 | Circuit Range N/A |
Day Range $3.97 - $4.08 | Year Range $2.09 - $4.58 | Volume 46,604 |
Average Traded $4.03 |
OraSure Technologies, Inc. Share Price Today
As of 10 August 2026, OraSure Technologies, Inc.'s share price is $4.05. The stock opened at $4.03, compared to its previous close of $3.99. During today's trading session, OraSure Technologies, Inc.'s share price traded between $3.97 and $4.08, with an average price of $4.03. Over the past 52 weeks, the stock has recorded a high of $4.58 and a low of $2.09. In terms of performance, OraSure Technologies, Inc.'s share price has risen by 28.57% over the last six months and is up 22.17% on a year-on-year basis.
OraSure Technologies, Inc. Share Price Chart
OraSure Technologies, Inc. Stock Fundamentals & Key Indicators
Market Cap $297.61M | PE Ratio (TTM) -4.31 | Dividend Yield N/A |
EPS (TTM) $-0.94 | Revenue (TTM) $115.02M | Return On Equity (TTM) -20.17% |
Profit Margin -59.76% | Debt to Equity 0.12 | Quarterly Earnings Growth YoY -204.24% |
OraSure Technologies, Inc. Quarterly Profit & Loss
All figures in USD
OraSure Technologies, Inc. Annual Profit & Loss
All figures in USD
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
OraSure Technologies, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $4.10 | $4.06 | -0.15% |
Jul 2026 | $4.46 | $4.07 | -8.75% |
Jun 2026 | $4.21 | $4.46 | +3.85% |
May 2026 | $3.02 | $4.29 | +41.12% |
Apr 2026 | $2.99 | $3.04 | +1.00% |
Mar 2026 | $3.11 | $3.01 | -4.44% |
Feb 2026 | $2.78 | $3.15 | +12.90% |
Jan 2026 | $2.42 | $2.79 | +15.29% |
Dec 2025 | $2.37 | $2.42 | +1.47% |
Nov 2025 | $2.73 | $2.38 | -12.96% |
Oct 2025 | $3.24 | $2.74 | -14.64% |
Sep 2025 | $3.29 | $3.21 | -3.17% |